The Setup: Everyone and Their Cousin Is Talking About Ozempic

I walked into my annual physical last month with a mental checklist like everyone else. Blood pressure. Cholesterol. That one weird spot on my shoulder I wanted checked out. But there was something else floating around in my head, something I’d been hearing everywhere for the past year or so: GLP-1 medications. Ozempic. Zepbound. Wegovy. The drugs that seemed to be simultaneously hailed as miracle solutions and vilified as cheating shortcuts.

My social media feeds had made it clear that these medications weren’t niche anymore. When prescriptions for GLP-1 receptor agonists increased by over 400 percent between 2022 and 2025, that wasn’t just a statistic I read—it was evident in the number of people I knew personally who were either taking them or seriously considering it. One in eight American adults have taken a GLP-1 medication at some point, according to recent polling data. That’s not fringe territory. That’s mainstream.

I went in skeptical. Not hostile, exactly, but skeptical. I’d spent enough time reading think pieces about pharmaceutical companies and the weight loss industrial complex to think I understood the situation. I thought I had opinions. Turns out, I had assumptions instead.

What I Thought I Knew (But Didn’t, Really)

Before that appointment, my mental model of GLP-1 drugs was basically this: they were for celebrities and wealthy people, they were a shortcut instead of “real” weight loss through diet and exercise, and they probably didn’t work any better than just trying harder. I’d read enough discourse about ozempic face and the ethical problems of pharmaceutical solutions to think I’d formed an informed opinion.

Here’s what was embarrassing about that mental model: it was mostly built on cultural narrative rather than actual data. I knew tirzepatide was out there. I’d heard the numbers thrown around. But I hadn’t actually sat down and understood what the research showed, or what my doctor might recommend for my specific situation. I had a feeling about it, which is not the same as understanding it.

When my doctor brought it up unprompted—not as a miracle cure, but as part of a straightforward conversation about my health markers—I realized how much of my skepticism was just reflexive defensiveness. I didn’t want to seem like I was taking the easy way out. I didn’t want to be part of a trend. Those are understandable feelings, but they’re not the same as good reasoning.

What My Doctor Actually Said (And What Changed)

She started by looking at my bloodwork and my weight over the past five years. We talked about my attempts at diet and exercise, the ones that worked temporarily and the ones that didn’t stick. She didn’t shame me or act like I hadn’t tried hard enough. She also didn’t act like medication was the only solution or the automatic solution.

Then she said something that shifted my thinking: “The American Medical Association updated its guidelines in 2025. GLP-1 medications are now listed as first-line treatment for obesity, the same level as lifestyle modification.” Not instead of. Alongside. She showed me research from the New England Journal of Medicine about tirzepatide, which demonstrated an average weight loss of 22.5 percent of body weight over 72 weeks in adults with obesity. I did the math in my head. For someone at my weight, that would be significant. Real. Not a marginal difference.

What struck me most was that she presented it as one tool among many, not as proof that I’d failed at the tools I already knew about. She talked about the barriers—cost being the biggest one, which affects 43 percent of people who try these medications according to the KFF GLP-1 medication tracking poll. She didn’t pretend that wasn’t a real problem. She also didn’t pretend that my past struggles with diet and exercise were character flaws, or that I just hadn’t wanted it badly enough.

I asked her straight up: “Is this just hype? Is this something pharma companies are pushing?” She acknowledged the business reality—Novo Nordisk’s Ozempic and Wegovy sales exceeded 25 billion dollars combined in 2025, making them some of the most profitable drugs ever made. That’s real. But she also pointed me to the New England Journal of Medicine obesity research, which isn’t funded by pharmaceutical marketing departments. The data exists independently of the business incentives.

The Uncomfortable Truth About Changing Your Mind

I’m writing this partly to share what I learned, but also to be honest about how uncomfortable it was to realize I’d been wrong. I’d had a confident opinion about something based on vibes and secondhand discourse rather than actual investigation. That’s an unsettling feeling once you notice it.

The thing about being the friend who admits when something doesn’t work is that you also have to be willing to admit when you’ve been too quick to dismiss something. I was skeptical of GLP-1 drugs for reasons that seemed principled—resisting pharmaceutical overreach, questioning whether medication was really necessary—but I was using those genuinely important concerns as cover for not actually doing the work to understand the science.

My doctor didn’t try to convince me to take anything. She gave me information, acknowledged the legitimate barriers, and told me to think about it. We talked about what else might help. We talked about my actual goals and what would be realistic. She treated me like someone capable of making a decision, not someone who needed to be saved from myself.

Where I’m At Now (And What This Really Taught Me)

I’m not on a GLP-1 medication right now. I’m exploring other options first, and that might work, or it might not. The point isn’t whether I end up taking it. The point is that I’m making that decision from actual information instead of cultural narratives and defensive assumptions.

What I took from that appointment goes beyond just understanding GLP-1 drugs better. It’s a reminder that changing your mind when you learn new things is okay. It’s not weakness. It’s not failure. It’s how people navigate a complicated world. The alternative—holding onto positions primarily because you’ve already stated them publicly—that’s the trap.

If you’re sitting where I was a few weeks ago, skeptical and maybe a little defensive about these medications, I get it. Some of that skepticism is probably healthy. But talk to your doctor about it, look at the actual research, and let yourself be surprised by what you learn. You might not end up taking anything. You might find that you want to. Either way, you’ll have made an informed decision instead of just accepting whatever story the internet told you.

What’s your experience been with this? Have you talked to your doctor about GLP-1 medications, or are you still in the skepticism phase? I’m genuinely curious what changed people’s minds, or what made them decide it wasn’t for them. Drop a comment—I’m not interested in the polished takes. I want to hear about the messy, real thinking.